Practical Examples in the Chromatographic Purification of Semaglutide
Table of contents
Introduction
Semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a cornerstone in the therapeutic landscape for Type 2 diabetes mellitus and chronic weight management.
However, the surge in clinical demand necessitates highly efficient, scalable, and robust production and purification frameworks to ensure product purity and patient safety.
Synthesis Methodologies and Associated Impurity Profiles
The manufacturing of Semaglutide involves complex chemical and biological processes, primarily utilizing two dominant technical routes.
1. Recombinant Fermentation Combined with Chemical Synthesis
This process involves preparing the product through a combination of biological fermentation and chemical synthesis. However, this route is prone to generating significant quantities of unintended impurities, which complicates downstream separation and purification while resulting in relatively low recovery rates.
2. Solid-Phase Peptide Synthesis (SPPS) and Fragment Condensation
An alternative manufacturing methodology utilizes traditional solid-phase peptide synthesis (SPPS) and fragment condensation techniques for the preparation of the peptide.
Examples: Purifying Fully Synthetic Semaglutide of Various Purity
Example 1: Crude Purity 59.65%
Stage 1: Ultisil XB-C8, 10 µm, 120 Å
Result:
- Purity: 94.56%
- Recovery: 80%
- Loading Capacity: 0.6% (v/v relative to stationary phase)
Stage 2: Xtimate C8, 10 µm, 120 Å
Result:
- Purity: 99.65%
- Recovery: 71%
- Loading Capacity: 0.56% (v/v relative to stationary phase)
Example 2: Crude Purity 82.75%
Packing Material: Ultisil XB-C8, 10 µm, 120 Å
Result:
- Purity: 99.15%
- Recovery: 71%
- Loading Capacity: 0.62% (v/v relative to stationary phase)
Conclusion
| Sample 1 | Sample 2 | |
|---|---|---|
| Crude purity % | 59.65 | 82.75 |
| Stage 1 purity % | 94.56 | 99.15 |
| Stage 1 recovery % | 80 | 71 |
| Stage 1 sample load % | 0.6 | 0.62 |
| Stage 2 purity % | 99.65 | |
| Stage 2 recovery % | 71 | |
| Stage 2 sample load % | 0.56 |
For a low-purity semaglutide, using Welch Ultisil XB-C8 (10 µm, 120 Å) and Xtimate C8 (10 µm, 120 Å) to perform a two-stage purification, the final purity is 99.65% with a total recovery rate of 56.8%. The loading capacity of the two stages are 0.6% and 0.56% relative to the stationary phase, respectively.
For a high-purity semaglutide, using Welch Ultisil XB-C8 (10 µm, 120 Å) to perform a single-stage purification, the final purity is 99.15% with a recovery of 71% and a loading capacity of 0.62% relative to the stationary phase.
Further Reading
The Ultisil BHS & CHS series packing materials are enhanced solutions to peptide purification (including semaglutide) that does not only excel in performance but is also more economic friendly. Read this article to learn further about this new packing material series!